Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 34 | 2023 | 5213 | 2.190 |
Why?
|
Deoxycytidine | 9 | 2020 | 825 | 1.300 |
Why?
|
Adenocarcinoma | 14 | 2023 | 6318 | 1.080 |
Why?
|
Neuropilin-1 | 3 | 2014 | 91 | 0.960 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 11410 | 0.870 |
Why?
|
Paclitaxel | 5 | 2023 | 1701 | 0.850 |
Why?
|
Carcinoma, Pancreatic Ductal | 9 | 2022 | 1607 | 0.820 |
Why?
|
Albumins | 4 | 2023 | 563 | 0.790 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2020 | 279 | 0.640 |
Why?
|
Neoplasms | 15 | 2022 | 21507 | 0.630 |
Why?
|
Diphenylamine | 2 | 2017 | 50 | 0.600 |
Why?
|
Fluorouracil | 7 | 2022 | 1609 | 0.570 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 524 | 0.570 |
Why?
|
Maximum Tolerated Dose | 9 | 2020 | 888 | 0.570 |
Why?
|
Immunoconjugates | 3 | 2021 | 889 | 0.560 |
Why?
|
GPI-Linked Proteins | 2 | 2020 | 433 | 0.540 |
Why?
|
Sirolimus | 2 | 2013 | 1559 | 0.520 |
Why?
|
Quinolines | 1 | 2018 | 721 | 0.440 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 981 | 0.440 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 1214 | 0.440 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 3770 | 0.400 |
Why?
|
Camptothecin | 2 | 2021 | 570 | 0.390 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 489 | 0.390 |
Why?
|
Antibodies, Monoclonal | 4 | 2018 | 9259 | 0.370 |
Why?
|
Thymidylate Synthase | 1 | 2010 | 74 | 0.370 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 462 | 0.370 |
Why?
|
Antineoplastic Agents | 9 | 2020 | 13635 | 0.350 |
Why?
|
Liver Neoplasms | 4 | 2021 | 4216 | 0.350 |
Why?
|
Protein Kinase Inhibitors | 6 | 2020 | 5502 | 0.350 |
Why?
|
Pyridines | 2 | 2019 | 2810 | 0.350 |
Why?
|
Neoadjuvant Therapy | 8 | 2022 | 2688 | 0.340 |
Why?
|
Angiogenesis Inhibitors | 3 | 2014 | 2037 | 0.340 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2013 | 623 | 0.340 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2018 | 2185 | 0.310 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2013 | 3562 | 0.310 |
Why?
|
Sulfonamides | 2 | 2017 | 1934 | 0.300 |
Why?
|
Receptors, CXCR4 | 1 | 2012 | 726 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 5148 | 0.300 |
Why?
|
Neoplasm Staging | 11 | 2021 | 10961 | 0.290 |
Why?
|
Biliary Tract Neoplasms | 2 | 2018 | 177 | 0.260 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.240 |
Why?
|
Aged | 37 | 2023 | 162698 | 0.240 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 970 | 0.230 |
Why?
|
Enhancer Elements, Genetic | 1 | 2010 | 1330 | 0.230 |
Why?
|
Middle Aged | 40 | 2022 | 212863 | 0.230 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 2102 | 0.220 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 86 | 0.210 |
Why?
|
Benzimidazoles | 2 | 2018 | 849 | 0.210 |
Why?
|
Colorectal Neoplasms | 4 | 2024 | 6726 | 0.210 |
Why?
|
Drug Administration Schedule | 5 | 2021 | 4935 | 0.210 |
Why?
|
Rectal Neoplasms | 2 | 2021 | 1192 | 0.200 |
Why?
|
Adult | 31 | 2022 | 213394 | 0.200 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 88 | 0.200 |
Why?
|
Humans | 73 | 2024 | 739398 | 0.200 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2530 | 0.190 |
Why?
|
Indolizines | 1 | 2020 | 37 | 0.190 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2001 | 143 | 0.190 |
Why?
|
Cyclic N-Oxides | 1 | 2020 | 78 | 0.190 |
Why?
|
Lymphoma | 2 | 2001 | 1873 | 0.190 |
Why?
|
Treatment Outcome | 17 | 2021 | 62693 | 0.190 |
Why?
|
Pyridinium Compounds | 1 | 2020 | 84 | 0.190 |
Why?
|
Mice, Nude | 4 | 2017 | 3692 | 0.180 |
Why?
|
Immunosuppressive Agents | 1 | 2013 | 4143 | 0.180 |
Why?
|
Piperidines | 2 | 2020 | 1597 | 0.180 |
Why?
|
Female | 44 | 2023 | 378853 | 0.180 |
Why?
|
Leucovorin | 4 | 2022 | 618 | 0.180 |
Why?
|
Aged, 80 and over | 16 | 2022 | 57650 | 0.170 |
Why?
|
Male | 41 | 2023 | 349022 | 0.170 |
Why?
|
Azetidines | 1 | 2020 | 142 | 0.170 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 4815 | 0.170 |
Why?
|
Neoplasm Transplantation | 2 | 2013 | 2084 | 0.160 |
Why?
|
Quinazolinones | 1 | 2020 | 223 | 0.160 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2020 | 217 | 0.160 |
Why?
|
Integrin alpha5beta1 | 1 | 2018 | 38 | 0.160 |
Why?
|
Administration, Oral | 4 | 2020 | 3909 | 0.160 |
Why?
|
Stromal Cells | 2 | 2001 | 1350 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 10945 | 0.150 |
Why?
|
Pyrrolidinones | 1 | 2018 | 119 | 0.150 |
Why?
|
Quinazolines | 2 | 2015 | 1356 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 284 | 0.150 |
Why?
|
Pancreas | 3 | 2020 | 1678 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 648 | 0.150 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2017 | 97 | 0.150 |
Why?
|
Purines | 1 | 2020 | 593 | 0.140 |
Why?
|
Integrins | 1 | 2001 | 845 | 0.140 |
Why?
|
Wnt Proteins | 1 | 2020 | 719 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2022 | 663 | 0.140 |
Why?
|
Antigens, Surface | 1 | 2020 | 1667 | 0.130 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2020 | 2933 | 0.130 |
Why?
|
Bone Marrow Purging | 1 | 1995 | 109 | 0.130 |
Why?
|
Vaccines | 1 | 2024 | 802 | 0.130 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 338 | 0.130 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3508 | 0.130 |
Why?
|
Ferrosoferric Oxide | 1 | 2016 | 364 | 0.120 |
Why?
|
Drug Interactions | 1 | 2019 | 1456 | 0.120 |
Why?
|
Transplantation, Heterologous | 2 | 2013 | 2381 | 0.120 |
Why?
|
Platinum | 1 | 2016 | 229 | 0.120 |
Why?
|
Retreatment | 1 | 2016 | 603 | 0.120 |
Why?
|
Sulfones | 2 | 2014 | 436 | 0.120 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1754 | 0.120 |
Why?
|
Hodgkin Disease | 1 | 2002 | 1413 | 0.120 |
Why?
|
Social Environment | 1 | 2019 | 1014 | 0.120 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 628 | 0.110 |
Why?
|
Glycine | 2 | 2014 | 674 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.110 |
Why?
|
Workplace | 1 | 2019 | 837 | 0.110 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1522 | 0.110 |
Why?
|
Mucin-1 | 1 | 2017 | 542 | 0.110 |
Why?
|
Biological Assay | 1 | 2016 | 653 | 0.110 |
Why?
|
Receptors, CXCR | 1 | 2012 | 53 | 0.110 |
Why?
|
Pyrazines | 1 | 2018 | 1232 | 0.110 |
Why?
|
Imidazoles | 1 | 2018 | 1207 | 0.100 |
Why?
|
ras Proteins | 2 | 2017 | 1062 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1674 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1305 | 0.100 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2012 | 128 | 0.100 |
Why?
|
Quality of Life | 5 | 2023 | 12640 | 0.100 |
Why?
|
Membrane Transport Proteins | 1 | 2017 | 1028 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2019 | 2015 | 0.100 |
Why?
|
Cyclin D1 | 1 | 2012 | 462 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 2015 | 0.090 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4832 | 0.090 |
Why?
|
Disease Progression | 4 | 2022 | 13237 | 0.090 |
Why?
|
Thrombosis | 1 | 2023 | 2961 | 0.090 |
Why?
|
Young Adult | 6 | 2021 | 56255 | 0.080 |
Why?
|
Patient Care Team | 1 | 2020 | 2527 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 888 | 0.080 |
Why?
|
Drug Synergism | 1 | 2013 | 1792 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2013 | 2345 | 0.080 |
Why?
|
Cell Line, Tumor | 3 | 2017 | 16646 | 0.080 |
Why?
|
Prognosis | 6 | 2022 | 28901 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5154 | 0.080 |
Why?
|
Bone Marrow | 1 | 1998 | 2933 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6361 | 0.080 |
Why?
|
Autophagy | 1 | 2016 | 1295 | 0.080 |
Why?
|
RNA Interference | 2 | 2017 | 2899 | 0.080 |
Why?
|
Cell Culture Techniques | 1 | 1995 | 1662 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3571 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 563 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 984 | 0.070 |
Why?
|
Drug Design | 1 | 2012 | 1088 | 0.070 |
Why?
|
Metabolome | 1 | 2013 | 881 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 3 | 2014 | 4555 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2001 | 6310 | 0.070 |
Why?
|
Retrospective Studies | 10 | 2023 | 76631 | 0.070 |
Why?
|
Registries | 1 | 2021 | 8039 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2017 | 2896 | 0.070 |
Why?
|
Cohort Studies | 6 | 2023 | 40389 | 0.060 |
Why?
|
Homozygote | 1 | 2010 | 1788 | 0.060 |
Why?
|
Glucose | 1 | 2017 | 4377 | 0.060 |
Why?
|
Demography | 1 | 2010 | 1650 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5702 | 0.060 |
Why?
|
Signal Transduction | 5 | 2017 | 23355 | 0.060 |
Why?
|
Mutation | 3 | 2020 | 29658 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 35326 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6871 | 0.060 |
Why?
|
Mesenteric Veins | 1 | 2023 | 89 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 3498 | 0.060 |
Why?
|
Contrast Media | 1 | 2016 | 5293 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2026 | 0.050 |
Why?
|
Chlorambucil | 1 | 2002 | 43 | 0.050 |
Why?
|
Cell Communication | 2 | 2001 | 1618 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2023 | 347 | 0.050 |
Why?
|
Procarbazine | 1 | 2002 | 181 | 0.050 |
Why?
|
Cell Adhesion | 2 | 2017 | 3137 | 0.050 |
Why?
|
Survival Rate | 3 | 2022 | 12761 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11347 | 0.050 |
Why?
|
CA-19-9 Antigen | 1 | 2022 | 110 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3453 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8605 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3504 | 0.050 |
Why?
|
Phosphorylation | 1 | 2012 | 8416 | 0.050 |
Why?
|
Azacitidine | 1 | 2022 | 344 | 0.050 |
Why?
|
Prednisolone | 1 | 2002 | 332 | 0.050 |
Why?
|
Portal Vein | 1 | 2023 | 433 | 0.050 |
Why?
|
Bleomycin | 1 | 2002 | 496 | 0.050 |
Why?
|
Integrin alpha4beta1 | 1 | 2001 | 120 | 0.050 |
Why?
|
Nitrates | 1 | 2022 | 265 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10247 | 0.050 |
Why?
|
Vinblastine | 1 | 2002 | 488 | 0.050 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 257 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2021 | 237 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 315 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 546 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 797 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 658 | 0.040 |
Why?
|
Mice | 4 | 2016 | 81002 | 0.040 |
Why?
|
Edema | 1 | 2023 | 791 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 686 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2016 | 8977 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 401 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 618 | 0.040 |
Why?
|
Animals | 7 | 2017 | 168368 | 0.040 |
Why?
|
Plasma Membrane Calcium-Transporting ATPases | 1 | 2017 | 16 | 0.040 |
Why?
|
Pentose Phosphate Pathway | 1 | 2017 | 125 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20055 | 0.040 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2017 | 80 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2001 | 1343 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 3101 | 0.040 |
Why?
|
Digoxin | 1 | 2017 | 251 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 976 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 692 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 727 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1004 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1977 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 903 | 0.030 |
Why?
|
Pancreatectomy | 1 | 2020 | 799 | 0.030 |
Why?
|
Doxorubicin | 1 | 2002 | 2218 | 0.030 |
Why?
|
Genotype | 1 | 2010 | 12951 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 4189 | 0.030 |
Why?
|
Job Satisfaction | 1 | 2019 | 536 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2020 | 20676 | 0.030 |
Why?
|
Culture | 1 | 2019 | 627 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9122 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2020 | 1771 | 0.030 |
Why?
|
Subcutaneous Fat | 1 | 2018 | 392 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1008 | 0.030 |
Why?
|
Radiotherapy | 1 | 2021 | 1526 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2872 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2013 | 38942 | 0.030 |
Why?
|
Carbon | 1 | 2017 | 684 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2019 | 2238 | 0.030 |
Why?
|
Muscles | 1 | 2018 | 1608 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 2247 | 0.030 |
Why?
|
Research | 1 | 2021 | 2001 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2001 | 3603 | 0.030 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2012 | 93 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1571 | 0.030 |
Why?
|
Calcium Signaling | 1 | 2017 | 721 | 0.030 |
Why?
|
Patient Participation | 1 | 2021 | 1441 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2017 | 1213 | 0.030 |
Why?
|
Prospective Studies | 3 | 2021 | 53037 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2687 | 0.030 |
Why?
|
Peptides | 1 | 2024 | 4395 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2021 | 5058 | 0.020 |
Why?
|
Cell Cycle Proteins | 2 | 2014 | 3433 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2012 | 129 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1904 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 802 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2217 | 0.020 |
Why?
|
Cell Division | 1 | 1998 | 4575 | 0.020 |
Why?
|
Amino Acids | 1 | 2017 | 1727 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15500 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1280 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2017 | 1331 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2012 | 911 | 0.020 |
Why?
|
Niacinamide | 1 | 2012 | 415 | 0.020 |
Why?
|
Lymphopenia | 1 | 2012 | 286 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4182 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2012 | 495 | 0.020 |
Why?
|
Transfection | 1 | 2017 | 5884 | 0.020 |
Why?
|
DNA Methylation | 1 | 2022 | 4269 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6722 | 0.020 |
Why?
|
Cell Survival | 1 | 1998 | 5877 | 0.020 |
Why?
|
United States | 3 | 2021 | 69573 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1995 | 1377 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 1655 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1407 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2012 | 12985 | 0.020 |
Why?
|
Time Factors | 2 | 2021 | 40050 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 888 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 788 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2022 | 14740 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6516 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2448 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3051 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2022 | 9387 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4391 | 0.020 |
Why?
|
Health Personnel | 1 | 2019 | 3203 | 0.020 |
Why?
|
Thalidomide | 1 | 2010 | 878 | 0.020 |
Why?
|
Pyrimidines | 1 | 2017 | 2918 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10398 | 0.020 |
Why?
|
Age Factors | 1 | 2002 | 18349 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15036 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5221 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1524 | 0.020 |
Why?
|
Protein Binding | 1 | 2017 | 9375 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7897 | 0.020 |
Why?
|
Risk Factors | 2 | 2020 | 71974 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13880 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12237 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3802 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20913 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12328 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13402 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7690 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6237 | 0.010 |
Why?
|
Apoptosis | 1 | 1998 | 9714 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 10455 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8400 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17384 | 0.010 |
Why?
|